ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 835

Generation of an Efficient CRISPR-Cas9 Editing Technique in Human Primary B Cells for the Targeted Study of Autoimmune Susceptibility Genes

Yuriy Baglaenko1, Dario Ferri2, Juan Carlos Zuniga-Pflucker3 and Joan E. Wither2,4,5, 1Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Immunology, University of Toronto, Toronto, ON, Canada, 3Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada, 4Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells, genetics and therapeutic targeting

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Autoimmunity is a complex, poly-genic disorder that culminates in multi-organ damage. In systemic lupus erythematosus (SLE), the prototypic autoimmune disorder, a breakdown of tolerance leads to erroneous immune cell activation and the production of disease-causing autoantibodies. B cell functional abnormalities appear to be central to this process and many of the lupus susceptibility genes identified by genome wide association studies (GWAS) are predicted to impact B cell selection, differentiation, signaling, and proliferation. However, their precise mechanisms of action in human B cells remain to be defined. A major challenge preventing the application of GWAS data to therapeutic potential is that animal models often do not recapitulate human phenotypes. In fact, a number of identified autoimmune disease-related genes are known to have differential expression in mice and humans. For this reason, it is important to investigate gene function directly in primary human B cells. To date, the methods for investigating gene function in human B cells has been limited by the relative rarity of many susceptibility alleles and ineffective or transient RNA silencing approaches. CRISPR-Cas9 technology, which uses customizable guide RNAs (gRNA) to direct the cutting of DNA by Cas9 enzymes, presents an unexplored opportunity for studying gene function directly in primary human lymphocytes. The aim of this study was to develop a robust CRISPR-Cas9 method for studying gene function directly in peripheral human B cells isolated from PBMCs.

Methods:

Primary human B cells were isolated from healthy donors using Ficoll-Paque gradients followed by negative magnetic sorting of B cells. Isolated B cells were nucleofected with CRISPR-Cas9 ribonuclear protein complexes and cultured on BAFF and CD40L expressing OP9 stroma for 7 days. Function was assessed by calcium flux assays and phoshosignaling using a flow cytometer.

Results:

Taking advantage of recent advances in genome editing technologies, we were able to successfully and robustly knockout CD22 in primary human B cells from healthy donors, achieving an average efficiency of 35% as measured by loss of cell surface expression. Using this highly adaptable system, we show that gRNA selection can have a profound impact on knockout efficiency and that B cell lines are not an effective proxy for this process. Consistent with the literature, knockout of CD22 in primary B cells resulted in the generation of activated/memory B cells with significantly increased expression of CD86. Furthermore, knockout of CD22 resulted in increased basal activation and as a consequence, total B cells had a reduced capacity for pSyk and pPLCγ signaling. Supporting this observation, IgD+ B cells were hyperresponsive to IgM stimulation with an increased capacity for calcium fluxing.

Conclusion: These findings demonstrate, for the first time, the ability to robustly knockout genes directly in primary human B cells. Using this approach, the role of CD22 in maintaining naïve B cells was confirmed in healthy donors. This methodology allows for the targeted study of autoimmune-related genes and their impact on B cell function.


Disclosure: Y. Baglaenko, None; D. Ferri, None; J. C. Zuniga-Pflucker, None; J. E. Wither, None.

To cite this abstract in AMA style:

Baglaenko Y, Ferri D, Zuniga-Pflucker JC, Wither JE. Generation of an Efficient CRISPR-Cas9 Editing Technique in Human Primary B Cells for the Targeted Study of Autoimmune Susceptibility Genes [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/generation-of-an-efficient-crispr-cas9-editing-technique-in-human-primary-b-cells-for-the-targeted-study-of-autoimmune-susceptibility-genes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/generation-of-an-efficient-crispr-cas9-editing-technique-in-human-primary-b-cells-for-the-targeted-study-of-autoimmune-susceptibility-genes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology